REDWOOD CITY, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be presenting at the 8th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Bel Air, California. The conference will be held on June 4-6, 2018.
Mr. Jeff Soinski, Avinger’s President and CEO will be presenting on Monday, June 4 at 1:30 pm Pacific time, with one-on-one meetings held throughout the day. His presentation will cover the Company’s Lumivascular platform, the only technology that combines real-time intravascular imaging with effective therapy for the treatment of PAD. Peripheral artery disease is projected to affect more than 21 million people in the United States by 2020.
The presentation will be available on webcast. To access the webcast, please use the following link: http://wsw.com/webcast/ldmicro14/avgr/
The webcast will also be available at Avinger's website at: www.avinger.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. LD Micro are investors, first and foremost.
What started out as a newsletter highlighting unique companies has transformed into several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure microcap index (LDMi) which covers stocks in North America with market capitalizations between $50-$300m.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the PantherisÒ family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Public Relations Contact:
Phil Preuss
VP of Marketing & Business Operations
Avinger, Inc.
(650) 241-7900
pr@avinger.com
Investor Contact:
Matt Ferguson
Chief Business Officer & CFO
Avinger, Inc.
(650) 241-7916
ir@avinger.com